Neurogene Inc. (NASDAQ:NGNE) Receives $74.17 Consensus PT from Analysts

Shares of Neurogene Inc. (NASDAQ:NGNE) have earned an average rating of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $74.1667.

A number of equities research analysts have commented on NGNE shares. Guggenheim started coverage on Neurogene in a research report on Tuesday, April 28th. They issued a “buy” rating and a $69.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research report on Tuesday, April 21st. Finally, Canaccord Genuity Group reduced their price target on Neurogene to $180.00 and set a “buy” rating on the stock in a research report on Monday, April 6th.

Neurogene Trading Up 3.1%

NASDAQ NGNE opened at $28.34 on Friday. The business’s 50-day moving average price is $25.28 and its two-hundred day moving average price is $21.93. Neurogene has a 12 month low of $14.65 and a 12 month high of $37.27. The firm has a market capitalization of $447.83 million, a PE ratio of -6.23 and a beta of 1.69.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.09). As a group, analysts forecast that Neurogene will post -5.74 earnings per share for the current fiscal year.

Insider Transactions at Neurogene

In other Neurogene news, CFO Christine Mikail Cvijic sold 9,600 shares of the company’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $31.25, for a total value of $300,000.00. Following the sale, the chief financial officer owned 93,640 shares in the company, valued at approximately $2,926,250. The trade was a 9.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stuart Cobb sold 6,797 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $20.81, for a total value of $141,445.57. Following the completion of the sale, the insider owned 30,497 shares in the company, valued at $634,642.57. This trade represents a 18.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 20,442 shares of company stock worth $525,622 in the last quarter. Corporate insiders own 11.68% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its stake in shares of Neurogene by 89.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after purchasing an additional 978 shares during the period. Daiwa Securities Group Inc. acquired a new position in shares of Neurogene in the 4th quarter valued at about $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Neurogene by 17.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after purchasing an additional 1,059 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Neurogene by 24.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock valued at $88,000 after purchasing an additional 1,000 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Neurogene in the 4th quarter valued at about $165,000. 52.37% of the stock is owned by institutional investors and hedge funds.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.